PARIS, FRANCE / ACCESSWIRE / August 10, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject to market and other conditions, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The timing, number of securities to be offered in the proposed offering and their price have not yet been determined.
This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
*****
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
SOURCE: ABIVAX